Real-world application of Wound, Ischemia, and foot Infection scores in peripheral arterial disease patients

Margaret E Smith; Drew J Braet; Jeremy Albright; Matthew A Corriere; Nicholas H Osborne; Peter Henke

doi:10.1016/j.jvs.2024.04.071

Real-world application of Wound, Ischemia, and foot Infection scores in peripheral arterial disease patients

J Vasc Surg. 2024 May 7:S0741-5214(24)01099-1. doi: 10.1016/j.jvs.2024.04.071. Online ahead of print.

Authors

Margaret E Smith¹, Drew J Braet², Jeremy Albright³, Matthew A Corriere², Nicholas H Osborne², Peter Henke²

Affiliations

¹ Division of Vascular Surgery, Department of Surgery, University of Colorado Anschutz School of Medicine at Denver, Aurora, CO. Electronic address: margaret.2.smith@cuanschutz.edu.
² Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI.
³ Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI.

PMID: 38723913
DOI: 10.1016/j.jvs.2024.04.071

Abstract

Objective: The Society for Vascular Surgery (SVS) Wound, Ischemia, and foot Infection (WIfI) classification system aims to risk stratify patients with chronic limb-threatening ischemia (CLTI), predicting both amputation rates and the need for revascularization. However, real-world use of the system and whether it predicts outcomes accurately after open revascularization and peripheral interventions is unclear. Therefore, we sought to determine the adoption of the WIfI classification system within a contemporary statewide collaborative as well as the impact of patient factor, and WIfI risk assessment on short- and long-term outcomes.

Methods: Using data from a large statewide collaborative, we identified patients with CLTI undergoing open surgical revascularization or peripheral vascular intervention (PVI) between 2016 and 2022. The primary exposure was preoperative clinical WIfI stage. Patients were categorized according to the SVS Lower Extremity Threatened Limb Classification System into clinical WIfI stages 1, 2, 3, or 4. The primary outcomes were 30-day and 1-year amputation and mortality rates. Multivariable logistic regression was performed to estimate the association of WIfI stage on postrevascularization outcomes.

Results: In the cohort of 17,417 patients, 83.4% (n = 14,529) had WIfI stage documented. PVIs were performed on 57.6% of patients, and 42.4% underwent an open surgical revascularization. Of the patients, 49.5% were classified as stage 1, 19.3% stage 2, 12.8% stage 3, and 18.3% of patients met stage 4 criteria. Stage 3 and 4 patients had higher rates of diabetes, congestive heart failure, and renal failure, and were less likely to be current or former smokers. One-half of stage 3 patients underwent open surgical revascularization, whereas stage 1 patients were most likely to have received a PVI (64%). As WIfI stage increased from 1 to 4, 1-year mortality increased from 12% to 21% (P < .001), 30-day amputation rates increased from 5% to 38% (P < .001), and 1-year amputation rates increased from 15% to 55% (P < .001). Finally, patients who did not have WIfI scores classified had significantly higher 30-day and 1-year mortality rates, as well as higher 30-day and 1-year amputation rates.

Conclusions: The SVS WIfI clinical stage is significantly associated with 1-year amputation rates in patients with CLTI after lower extremity revascularization. Because nearly 55% of stage 4 patients require a major amputation within 1 year of intervention, this finding study supports use of the WIfI classification system in clinical decision-making for patients with CLTI.

Keywords: Chronic limb-threatening ischemia; Lower extremity revascularization; Revascularization benefit; Risk stratification; WIfI.